2019 has been a transformational year for ReNeuron, marked by impressive initial data from the human retinal progenitor cells (hRPC) programme in retinitis pigmentosa (RP) and the initiation of a China partnership with Fosun Pharma (milestone payments of up to £80m and double-digit royalties). In the RP programme, positive data were presented at the AAO annual meeting in San Francisco on eight patients, which further reinforces the data presented earlier in the year. However, long-term
19 Dec 2019
ReNeuron Group - A transformational year
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group - A transformational year
ReNeuron Group plc (RENE:LON) | 0 0 0.0% | Mkt Cap: 1.74m
- Published:
19 Dec 2019 -
Author:
Dr Daniel Wilkinson -
Pages:
13
2019 has been a transformational year for ReNeuron, marked by impressive initial data from the human retinal progenitor cells (hRPC) programme in retinitis pigmentosa (RP) and the initiation of a China partnership with Fosun Pharma (milestone payments of up to £80m and double-digit royalties). In the RP programme, positive data were presented at the AAO annual meeting in San Francisco on eight patients, which further reinforces the data presented earlier in the year. However, long-term